^
Association details:
Biomarker:GNAQ mutation
Cancer:Uveal Melanoma
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis

Excerpt:
...tumors from patients who benefited were confirmed by molecular sequencing to harbor either GNAQ or GNA11 mutations, but the patients had either no liver involvement or had liver metastases of maximal diameter <1.2 cm...Median progression-free survival was 11.0 months (Figure 1A) and median overall survival was not reached (Figure 1B; median follow-up, 11.1 months; range, 0.4–25.5 months).
DOI:
https://doi.org/10.6004/jnccn.2018.7070